These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33843698)

  • 1. A Call to Action: Promoting Diversity, Equity, and Inclusion in Parkinson's Research and Care.
    Siddiqi B; Koemeter-Cox A
    J Parkinsons Dis; 2021; 11(3):905-908. PubMed ID: 33843698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing the Fostering Inclusivity in Research Engagement for Underrepresented Populations in Parkinson's Disease study.
    Sanchez AV; Ison JM; Hemley H; Willis A; Siddiqi B; Macklin EA; Ulysse C; Reynolds M; Schwarzschild MA; Jackson JD
    Contemp Clin Trials; 2022 Apr; 115():106713. PubMed ID: 35202842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moving the Dial Toward Equity in Parkinson's Disease Clinical Research: a Review of Current Literature and Future Directions in Diversifying PD Clinical Trial Participation.
    Adrissi J; Fleisher J
    Curr Neurol Neurosci Rep; 2022 Aug; 22(8):475-483. PubMed ID: 35713775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of the U.S. safety & health workforce: Opportunities for academic diversity, equity, and inclusion through a leak-proof career pathway.
    Olawoyin R; Ogutu J
    J Safety Res; 2023 Sep; 86():100-106. PubMed ID: 37718036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient Perspectives on Deep Brain Stimulation Clinical Research in Early Stage Parkinson's Disease.
    Heusinkveld L; Hacker M; Turchan M; Bollig M; Tamargo C; Fisher W; McLaughlin L; Martig A; Charles D
    J Parkinsons Dis; 2017; 7(1):89-94. PubMed ID: 27911344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial and Social Disparities in Health and Health Care Delivery among Patients with Parkinson's Disease and Related Disorders in a Multiracial Clinical Setting.
    Nwabuobi L; Agee J; Gilbert R
    J Cross Cult Gerontol; 2021 Sep; 36(3):253-263. PubMed ID: 34398367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience.
    Dobkin RD; Amondikar N; Kopil C; Caspell-Garcia C; Brown E; Chahine LM; Marras C; Dahodwala N; Mantri S; Standaert DG; Dean M; Shoulson I; Marek K; Katz A; Korell M; Riley L; Tanner CM;
    J Parkinsons Dis; 2020; 10(2):665-675. PubMed ID: 32250321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.
    Nalls MA; McLean CY; Rick J; Eberly S; Hutten SJ; Gwinn K; Sutherland M; Martinez M; Heutink P; Williams NM; Hardy J; Gasser T; Brice A; Price TR; Nicolas A; Keller MF; Molony C; Gibbs JR; Chen-Plotkin A; Suh E; Letson C; Fiandaca MS; Mapstone M; Federoff HJ; Noyce AJ; Morris H; Van Deerlin VM; Weintraub D; Zabetian C; Hernandez DG; Lesage S; Mullins M; Conley ED; Northover CA; Frasier M; Marek K; Day-Williams AG; Stone DJ; Ioannidis JP; Singleton AB;
    Lancet Neurol; 2015 Oct; 14(10):1002-9. PubMed ID: 26271532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
    Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ
    J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395
    [No Abstract]   [Full Text] [Related]  

  • 11. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
    Healy DG; Falchi M; O'Sullivan SS; Bonifati V; Durr A; Bressman S; Brice A; Aasly J; Zabetian CP; Goldwurm S; Ferreira JJ; Tolosa E; Kay DM; Klein C; Williams DR; Marras C; Lang AE; Wszolek ZK; Berciano J; Schapira AH; Lynch T; Bhatia KP; Gasser T; Lees AJ; Wood NW;
    Lancet Neurol; 2008 Jul; 7(7):583-90. PubMed ID: 18539534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Michael J. Fox Foundation for Parkinson's Research Strategy to Advance Therapeutic Development of PINK1 and Parkin.
    Padmanabhan S; Polinski NK; Menalled LB; Baptista MAS; Fiske BK
    Biomolecules; 2019 Jul; 9(8):. PubMed ID: 31344817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease.
    Kane PB; Benjamin DM; Barker RA; Lang AE; Sherer T; Kimmelman J
    J Parkinsons Dis; 2020; 10(3):1047-1055. PubMed ID: 32333550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing Efficiency of Recruitment in Early Parkinson's Disease Trials: A Case Study Examination of the STEADY-PD III Trial.
    Berk S; Greco BL; Biglan K; Kopil CM; Holloway RG; Meunier C; Simuni T
    J Parkinsons Dis; 2017; 7(4):685-693. PubMed ID: 29103052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exercise- and strategy-based physiotherapy-delivered intervention for preventing repeat falls in people with Parkinson's: the PDSAFE RCT.
    Ashburn A; Pickering R; McIntosh E; Hulbert S; Rochester L; Roberts HC; Nieuwboer A; Kunkel D; Goodwin VA; Lamb SE; Ballinger C; Seymour KC
    Health Technol Assess; 2019 Jul; 23(36):1-150. PubMed ID: 31339100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of an online portal to facilitate clinical trial recruitment: a preliminary analysis of Fox Trial Finder.
    Rocker C; Cappelletti L; Marshall C; Meunier CC; Brooks DW; Sherer T; Chowdhury S
    J Parkinsons Dis; 2015; 5(1):55-66. PubMed ID: 25624422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in Parkinson's disease: a funder's perspective.
    Frasier M; Chowdhury S; Eberling J; Sherer T
    Biomark Med; 2010 Oct; 4(5):723-9. PubMed ID: 20945984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial and Ethnic Disparities in Parkinson Disease: A Call to Action.
    Aamodt WW; Willis AW; Dahodwala N
    Neurol Clin Pract; 2023 Apr; 13(2):e200138. PubMed ID: 37064587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interview with Mark Frasier: a Michael J Fox Foundation perspective on precision medicine in Parkinson's.
    Frasier MA
    Per Med; 2017 Jan; 14(1):13-15. PubMed ID: 29749821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.